RHB Research Institute has initiated coverage on Hyphens Pharma with a "buy" and a target price of S$0.25, believing that the company's speciality pharma principals and proprietary brands segments...

HEALTHCARE veteran Lim See Wah's rejection from medical school more than three decades ago turned out to be a significant pivot in his entrepreneurial journey.